Mark Tarnopolsky, McMaster University
Pediatrics
Professor
Hamilton, Ontario
tarnopol@mcmaster.ca
Office:
(905) 525-9140 ext. 75226
Expert In
Bio/Research
The overall goal of my research program is to discover and evaluate therapies that will enhance muscle function in people with acquired and genetic neuromuscular diseases and mitochondrial dysfunction. We have a particular interest in the potential for exercise, pharmacological and nutraceutical ...
Click to Expand >>
Click to Expand >>
Bio/Research
The overall goal of my research program is to discover and evaluate therapies that will enhance muscle function in people with acquired and genetic neuromuscular diseases and mitochondrial dysfunction. We have a particular interest in the potential for exercise, pharmacological and nutraceutical interventions to enhance muscle function and improve muscle mass. Our program spans the research disciplines from cell culture all the way to small-scale clinical trials. We have been successful at very rapidly turning basic biological principles into proof of concept studies and completing small-scale clinical trials in patients with muscle and mitochondrial dysfunction. The main underlying theme of much of my research is related to mitochondrial dysfunction and genetic diseases affecting the mitochondria, but also towards conditions associated with mitochondrial dysfunction including aging, immoblization, type 2 diabetes and obesity. Our program consists of a large staff with three research assistants, and animal technician, two laboratory technicians, eight PhD students, one to two postdoctoral fellows and a host of 4th year and summer students. We have a large number of clinical and basic science collaborators both at McMaster University, nationally and internationally and collaborate openly to advance science in this area towards the ultimate goal of improving function in the patients with neuromuscular and mitochondrial disorder.
We are currently involved in randomized clinical trial looking at the effective Deferiprone in patients with Friedreich’s ataxia. We are also finalizing the details for a randomized double blind trial looking at triacetyluridine in the treatment of mitochondrial cytopathies and hope to start this later in 2009.
Click to Shrink <<
We are currently involved in randomized clinical trial looking at the effective Deferiprone in patients with Friedreich’s ataxia. We are also finalizing the details for a randomized double blind trial looking at triacetyluridine in the treatment of mitochondrial cytopathies and hope to start this later in 2009.
Click to Shrink <<